Bumrungrad International Hospital, led by Chairat Neruntarat, MD, Professor, Otolaryngology Specialist and Sleep Otolaryngology Specialist, Vitchaphan Hemrungrojn, MD, Otolaryngology Specialist, Head and Neck Surgeon, and Sinus Surgeon, and Darakul Pornsriniyom, MD, Neurology Specialist and Sleep Medicine Specialist, held a media group interview to announce Bumrungrad’s newest treatment for snoring and sleep apnea, hypoglossal nerve stimulation, or HNS.
HNS is an effective solution for sleep apnea patients who are unable to use a CPAP machine. Designed to fit modern lifestyles, HNS offers both convenience and comfort—it is an implantable device that operates silently without disturbing noise and can be easily controlled with a portable remote.
The STAR Trial (Stimulation Therapy for Apnea Reduction) confirmed that HNS treatment can reduce the number of sleep apnea episodes for patients. From the trial, the average number of apnea episodes decreased from 29.3 to just 9 per hour. HNS has been approved by both the U.S. Food and Drug Administration (FDA) and the Thai Food and Drug Administration (TFDA). So far, more than 100,000 patients worldwide — including those in the United States, Europe, Japan, and Singapore — have been successfully treated with HNS, ensuring proven effectiveness and safety.
Last modify: August 29, 2025